Target intelligence / Profile preview

Atrioventricular conduction

Molecular classification
Other (physiological process; not a molecule, gene, or protein), (For reference, the relevant anatomical structure is the "Atrioventricular node," which is a collection of specialized cardiac muscle cells.)
01

Overview

"Atrioventricular conduction" refers to the physiological process by which electrical impulses are transmitted from the atria to the ventricles via the atrioventricular node and the bundle of His[1][2][4]. This process plays a critical role in coordinating the timing of atrial and ventricular contractions, ensuring efficient pumping of blood throughout the circulatory system. Disruption or delay in AV conduction can result in arrhythmias, ranging from first-degree AV block (prolonged conduction) to complete heart block (absent conduction). While the process itself is not a molecular target, various drugs can modulate AV conduction, typically by acting on the ion channels and cell signaling pathways within the AV node.\n\nFor structured molecular target information, the correct entry would be "Atrioventricular node" (AV node), a specialized cluster of cardiac muscle cells, not "atrioventricular conduction" (the process).

Other names
AV conductionCardiac conduction (when referring to the AV segment)
02

Mechanism of action

Inhibition or modulation of AV nodal conduction to slow heart rate or treat arrhythmias\nEnhancement of vagal tone (parasympathomimetic effect)\nBlockage of calcium or beta-adrenergic signaling to decrease conduction velocity through the AV node

03

Biological functions

Coordination of cardiac electrical impulsesDelay of atrial signal to synchronize ventricular contraction
04

Disease associations

Cardiovascular disease (conditions involving AV conduction disturbance, such as heart block, arrhythmia)Other (e.g., congenital or acquired AV block)
05

Safety considerations

Risk of excessive AV nodal blockade leading to bradycardia or complete heart blockProarrhythmic effects if underlying conduction abnormalities exist
06

Interacting drugs

Beta-blockers

3 more in the full profile.

07

Biomarkers

Electrocardiogram (ECG) PR interval (measures AV conduction time)ECG evidence of AV block or arrhythmia

Beyond the preview

Go deeper on Atrioventricular conduction.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Atrioventricular conduction.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call